This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
May 12, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive top-line results of three completed Phase III clinical trials in patients with type 2 diabetes for basal insulin peglispro (BIL), which is being studied as a once-daily treatment for both type 1 and type 2 diabetes. The primary efficacy endpoint of non-inferior reduction in hemoglobin A1c (HbA1c) compared to insulin glargine was met in all three trials. Having met the primary endpoints, superiority for HbA1c lowering was examined and, in all three trials, BIL showed a statistically superior reduction in HbA1c compared with insulin glargine.
The clinical trials evaluated three specific populations of patients with type 2 diabetes: those who were not previously taking insulin (IMAGINE-2); those taking basal insulin with mealtime insulin (IMAGINE-4); and those currently taking a basal insulin (IMAGINE-5). All three clinical trials compared BIL, an investigational basal insulin, with insulin glargine.
"These results are promising. Basal insulin peglispro is the first basal insulin to demonstrate consistently superior HbA1c reduction versus insulin glargine in Phase III clinical trials," said
Enrique Conterno, president, Lilly Diabetes. "If approved, BIL could offer a differentiated profile and provide an important new treatment option for patients with diabetes. We are on track to make regulatory filings by Q1 next year."
These clinical studies also evaluated the secondary endpoints of nocturnal hypoglycemia rates and changes in weight. In all three clinical trials, patients taking BIL experienced statistically significant lower rates of nocturnal hypoglycemia than those taking insulin glargine.
In addition, patients taking BIL had comparable to statistically significant less weight gain.
"In patients with type 2 diabetes taking insulin glargine, nocturnal hypoglycemia and weight gain may be barriers to improving glycemic control. The fact that patients treated with BIL had lower rates of nocturnal hypoglycemia and comparable to less weight gain while achieving superior improvements in glycemic control is noteworthy," said
David Kendall, M.D., distinguished medical fellow, Lilly Diabetes.
Additional Safety Results The additional safety findings in these Phase III clinical trials were generally consistent with findings reported in the BIL Phase II clinical trial in patients with type 2 diabetes.
In all three clinical trials, patients taking BIL had a small but statistically significant increase in triglycerides. In IMAGINE-4 and IMAGINE-5, there was a corresponding small but statistically significant reduction in HDL (high-density lipoprotein) cholesterol compared with those taking insulin glargine; this was not observed in IMAGINE-2. In IMAGINE-2 and IMAGINE-4, changes in LDL (low-density lipoprotein) cholesterol were not significantly different in patients taking BIL compared with those taking insulin glargine. In IMAGINE-5, LDL significantly decreased at 52 weeks in BIL-treated patients compared with those taking insulin glargine. In an analysis across clinical trials completed to date in patients with type 2 diabetes, the rates of adverse cardiovascular events among patients taking BIL and those taking insulin glargine were similar, with the upper limit of the 95 percent confidence interval below 1.8.